Mayo Clinic, Baxter Ventures and Velocity Pharmaceutical Development LLC, recently collaborated to form Vitesse Biologics LLC, which is specially structured to further speed and advance innovative therapeutics for oncology, immunology and hematology.
"Delivering innovative treatments to address unmet patient needs is at the very core of everything we do and drives our ongoing R&D focus," Baxter BioScience President Ludwig Hantson said. "By creating Vitesse, our business is executing on a new concept in early stage R&D by leveraging the expertise of industry-leading partners to accelerate the identification and development of novel biologic treatments that could eventually contribute to unmet patient needs while enhancing the Baxalta commercial portfolio."
This unique collaboration will focus on encouraging the development of protein- and antibody-based therapeutics.
"We are excited about the possibilities for this new collaboration, and particularly for this new model for early stage drug development," Mayo Clinic Executive Dean for Research Greg Gores said. "Our goal is to identify new, useful therapeutics to address the unmet needs of our patients."
Velocity CEO David Collier said he feels fortunate to have world-class partners in this project.
"We believe that the combination of the development and manufacturing expertise offered by Baxter BioScience and the clinical capabilities of the Mayo Clinic, working in conjunction with our team at (Velocity), will produce a series of very promising new therapeutics developed in a more rapid and cost-efficient manner," he said.